Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.
Recruiting · NCT07029230 · Observational (researchers observe without assigning treatment) · Lead sponsor: Martin Schweiger
View the official record on ClinicalTrials.gov →What this trial is about
Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
Who can take part
Age range
Up to 18 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Consented for cardiopulmonary bypass surgery for cardiac reason
- Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language
Exclusion criteria
- Know genetic life limiting conditions
- Syndrome patients who are scheduled or highly likely to be operated on more than one organ
- Body weight at time of surgery less than 2.5 kg
- Being recruited and enrolled for an interventional study protocol
Where it is running
1 location listed.
- University Children's Hospital Zurirch - Zurich, Canton of Zurich, Switzerland